1. Home
  2. SE vs ARGX Comparison

SE vs ARGX Comparison

Compare SE & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sea Limited each representing one

SE

Sea Limited each representing one

N/A

Current Price

$95.19

Market Cap

55.9B

ML Signal

N/A

Logo argenx SE

ARGX

argenx SE

N/A

Current Price

$939.90

Market Cap

58.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SE
ARGX
Founded
2009
2008
Country
Singapore
Netherlands
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
55.9B
58.4B
IPO Year
2017
2017

Fundamental Metrics

Financial Performance
Metric
SE
ARGX
Price
$95.19
$939.90
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
29
10
Target Price
$156.65
★ $1,180.17
AVG Volume (30 Days)
★ 2.5M
203.7K
Earning Date
11-10-2026
10-22-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$35.78
$47.90
Revenue Next Year
$22.80
$21.64
P/E Ratio
$49.15
★ $33.69
Revenue Growth
N/A
N/A
52 Week Low
$77.05
$661.85
52 Week High
$193.48
$1,072.75

Technical Indicators

Market Signals
Indicator
SE
ARGX
Relative Strength Index (RSI) 29.63 47.73
Support Level $81.51 $836.30
Resistance Level $98.89 $1,072.75
Average True Range (ATR) 2.95 18.68
MACD -0.69 -5.14
Stochastic Oscillator 0.95 45.67

Price Performance

Historical Comparison
SE
ARGX

About SE Sea Limited each representing one

Sea started as a gaming business, Garena, but in 2015 expanded into e-commerce. Sea operates Southeast Asia's largest e-commerce company, Shopee, in terms of gross merchandise value. Shopee is a hybrid consumer-to-consumer and business-to-consumer marketplace platform operating in Indonesia, Taiwan, Vietnam, Thailand, Malaysia, the Philippines, and Brazil. For Garena, Free Fire is the key revenue-generating game. Sea's third business, Monee, provides lending, payment, digital banking, and insurance services. As of March 2025, Forrest Li, the founder, chair, and CEO, owned 59.1% of the voting power. Tencent owned 18.5% of issued shares with no voting power.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: